In a nutshell
This study aimed to investigate medications to treat overactive bladder (OAB). This study found that mirabegron (Myrbetriq) and antimuscarinics are similarly effective in treating OAB.
Some background
Overactive bladder (OAB) occurs when the bladder muscle is too active. Instead of staying at rest as urine fills the bladder, the bladder contracts. This causes a person to feel a sudden and sometimes overwhelming urge to urinate even when the bladder is not full. Treatments for OAB can include antimuscarinics (eg. tolterodine, oxybutynin) and mirabegron.
It is unclear which treatment is better.
Methods & findings
This study included 1514 patients. 73.5% were female. Mirabegron was started by 613 patients and antimuscarinics by 901 patients. Questionnaires were filled by patients at the beginning of the study and at months 1, 3, 6, and 12.
OAB symptoms improved for people on both antimuscarinics and mirabegron. Those who had worse symptoms at the start experienced better improvements. Greater improvements were also seen in people who had not been treated before, and in Hispanic people.
Side-effects were dry-mouth, constipation, headache, and dizziness. These were experienced by people on both medications.
The bottom line
This study found that mirabegron and antimuscarinics are similarly effective in treating OAB.
Published By :
Advances in therapy
Date :
Jun 20, 2019
